Creative Medical Technology Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Creative Medical Technology Holdings, Inc. (CELZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$12.36 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2021-11-15
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-09-30 was -$138.73K.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-06-30 was -$4.10M.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2021-03-31 was -$8.12M, a 1181.56% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-12-31 was $4.53M, a 50.79% increase year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2020 was $2.80M, a 5.26% increase from fiscal 2019.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was $2.66M, a 75.01% decline from fiscal 2018.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was $10.63M, a 4220.54% increase from fiscal 2017.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2017 was $245.96K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$138.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$4.24M derived: sum of 2 quarters · filed 2021-11-15 | -$12.36M 10-Q · filed 2021-11-15 | -$7.83M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$12.23M 10-Q · filed 2021-08-16 | -$7.69M derived: sum of 3 quarters · filed 2021-08-16 | -$8.19M derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | -$8.12M 10-Q · filed 2021-05-17 | -$3.59M derived: sum of 2 quarters · filed 2021-05-17 | -$4.09M derived: sum of 3 quarters · filed 2021-05-17 | -$6.08M derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $4.04M derived: sum of 2 quarters · filed 2021-03-17 | $2.04M derived: sum of 3 quarters · filed 2021-03-17 | $2.80M 10-K · filed 2021-03-17 |
| 2020-09-30 | -$497.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$2.49M derived: sum of 2 quarters · filed 2020-11-13 | -$1.74M 10-Q · filed 2020-11-13 | $1.27M derived: sum of 4 quarters · filed 2020-11-13 |
| 2020-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$1.24M 10-Q · filed 2020-08-14 | $1.77M derived: sum of 3 quarters · filed 2020-08-14 | $332.77K derived: sum of 4 quarters · filed 2020-08-14 |
| 2020-03-31 | $751.22K 10-Q · filed 2020-05-15 | $3.76M derived: sum of 2 quarters · filed 2020-05-15 | $2.33M derived: sum of 3 quarters · filed 2020-05-15 | $2.16M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $1.57M derived: sum of 2 quarters · filed 2020-04-06 | $1.41M derived: sum of 3 quarters · filed 2020-04-06 | $2.66M 10-K · filed 2020-04-06 |
| 2019-09-30 | -$1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$1.60M derived: sum of 2 quarters · filed 2019-11-14 | -$351.30K 10-Q · filed 2019-11-14 | $19.61M derived: sum of 4 quarters · filed 2019-11-14 |
| 2019-06-30 | -$166.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $1.08M 10-Q · filed 2019-08-13 | $21.04M derived: sum of 3 quarters · filed 2019-08-13 | $16.53M derived: sum of 4 quarters · filed 2019-08-13 |
| 2019-03-31 | $1.25M 10-Q · filed 2019-05-20 | $21.21M derived: sum of 2 quarters · filed 2019-05-20 | $16.70M derived: sum of 3 quarters · filed 2019-05-20 | $13.54M derived: sum of 4 quarters · filed 2019-05-20 |
| 2018-12-31 | $19.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $15.45M derived: sum of 2 quarters · filed 2019-04-01 | $12.30M derived: sum of 3 quarters · filed 2019-04-01 | $10.63M 10-K · filed 2019-04-01 |
| 2018-09-30 | -$4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$7.67M derived: sum of 2 quarters · filed 2018-11-14 | -$9.34M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$4.82M 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | -$1.67M 10-Q · filed 2018-08-03 | |||
| 2017-12-31 | $245.96K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |